Pegfilgrastim biosimilar - Merck KGaA

Drug Profile

Pegfilgrastim biosimilar - Merck KGaA

Alternative Names: MSB-11455

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck KGaA
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 22 Aug 2017 Phase-I clinical trials in Cancer (In volunteers) in Australia (SC) (NCT03251248)
  • 21 Aug 2017 Phase-I clinical trials in Cancer (In volunteers) in New Zealand (SC) (NCT03251339)
  • 21 Aug 2017 Merck KGaA plans a phase I trial in Healthy subjects in August 2017 (NCT03251248)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top